Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Seiichiro Mitani"'
Autor:
Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, Hiroaki Kanemura, Seiichiro Mitani, Kaoru Tanaka, Hisato Kawakami, Yo Kishimoto, Yasuharu Haku, Katsuhiro Ito, Toshiyuki Sato, Chihiro Suminaka, Mami Yamaki, Yasutaka Chiba, Tomonori Yaguchi, Koichi Omori, Takashi Kobayashi, Kazuhiko Nakagawa, Tasuku Honjo, Hidetoshi Hayashi
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels
Externí odkaz:
https://doaj.org/article/ca0552f7ccdf42e3ad9e80f1d87a4c8b
Autor:
Akira Ooki, Taroh Satoh, Kei Muro, Atsuo Takashima, Shigenori Kadowaki, Daisuke Sakai, Takashi Ichimura, Seiichiro Mitani, Toshihiro Kudo, Keisho Chin, Shigehisa Kitano, Dung Thai, Marianna Zavodovskaya, JieJane Liu, Narikazu Boku, Kensei Yamaguchi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. In preclinical models, MMP9 inhibitors have been shown to enha
Externí odkaz:
https://doaj.org/article/47b63337491a4ba288e5e4723a34c5c6
Autor:
Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, Seiichiro Mitani, Masato Komoda, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Taito Esaki, Takako Eguchi Nakajima, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months.
Externí odkaz:
https://doaj.org/article/ffc380b74963483f8c6fa47268c6861c
Autor:
Sadayuki Kawai, Naoki Fukuda, Shun Yamamoto, Seiichiro Mitani, Katsuhiro Omae, Takeru Wakatsuki, Ken Kato, Shigenori Kadowaki, Daisuke Takahari, Narikazu Boku, Kei Muro, Nozomu Machida
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third- or lat
Externí odkaz:
https://doaj.org/article/eb8b100e1efb473587bd1cadee493b61
Autor:
Seiichiro Mitani, Shigenori Kadowaki, Isao Oze, Toshiki Masuishi, Yukiya Narita, Hideaki Bando, Sachiyo Oonishi, Yutaka Hirayama, Tsutomu Tanaka, Masahiro Tajika, Yutaro Koide, Takeshi Kodaira, Tetsuya Abe, Kei Muro
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 394-400 (2020)
Abstract Background Esophageal cancer is associated with synchronous or metachronous cancer at other primary sites. However, few studies have evaluated the second malignancies after the treatment of esophageal cancer. The present study aimed to clari
Externí odkaz:
https://doaj.org/article/e9afff41ba084af19045c129c3d2427e
Autor:
Atsuo Takashima, Narikazu Boku, Taroh Satoh, Shigenori Kadowaki, Kei Muro, Shigehisa Kitano, Kensei Yamaguchi, Keisho Chin, Marianna Zavodovskaya, Dung Thai, Akie Kimura Yoshikawa, Takashi Ichimura, Daisuke Sakai, Toshihiro Kudo, Seiichiro Mitani, JieJane Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/7cc785fafdf148689d07c0a9e332c912
Autor:
Kazunori Honda, Bishal Gyawali, Masashi Ando, Ryosuke Kumanishi, Kyoko Kato, Keiji Sugiyama, Seiichiro Mitani, Toshiki Masuishi, Yukiya Narita, Hideaki Bando, Hiroya Taniguchi, Shigenori Kadowaki, Takashi Ura, Kei Muro
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
PURPOSE: We previously reported on the pilot study assessing the feasibility of using the Japanese translation of the Comprehensive Score for Financial Toxicity (COST) tool to measure financial toxicity (FT) among Japanese patients with cancer. In th
Externí odkaz:
https://doaj.org/article/65301ba3b90c4fffac9baa39cb660bf7
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 1, Pp 304-310 (2019)
Here, we report the four cases with metastatic esophageal squamous cell carcinoma pretreated with standard chemotherapy who then received salvage-line chemotherapy with oxaliplatin and 5-fluorouracil plus l-leucovorin (FOLFOX) at our institution. We
Externí odkaz:
https://doaj.org/article/33d6d16a8ced405087d626d327655621
Autor:
Kazunori Honda, Masashi Ando, Keiji Sugiyama, Seiichiro Mitani, Toshiki Masuishi, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Takashi Ura, Kei Muro
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 3, Pp 863-870 (2017)
Angiosarcoma of the heart is an uncommon soft tissue sarcoma. A few cases of disseminated intravascular coagulation (DIC) associated with angiosarcoma occurring in various organs, but not the heart, have been reported. Although taxane is commonly use
Externí odkaz:
https://doaj.org/article/e1cbe96da1f64eda8ff8f7dcda81ac12
Autor:
Seiichiro Mitani, Hiroya Taniguchi, Keiji Sugiyama, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Shigenori Kadowaki, Takashi Ura, Masashi Ando, Masahiro Tajika, Yasushi Yatabe, Kei Muro
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. Recently, clinical trials have been conducted to improve outcomes of second or later lines of chemotherapy. However, t
Externí odkaz:
https://doaj.org/article/02a3947da7a14667a2dc215900912389